Clinical trials: Depressive; Behavioral Disorder
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
To evaluate the efficacy of two fixed doses of SR58611A (175 mg q12 and 350 mg q12) compared to placebo in patients with Major Depressive Disorder (MDD) using paroxetine (20 mg qd) as positive control.
- Trial name
- NCT00385307
- Testing
- amibegron (SR58611A)
- Where
- United States
- Volunteers
- 680 people
- Sponsor
- Sanofi
Major Depressive Disorder, Anxiety Disorders
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
The current study will test the causal relationship between elevated levels of cortisol and the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to environmental threat.
- Trial name
- 5-HTTLPR (NCT01710202)
- Testing
- Hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Major Depressive Disorder, Anhedonia
Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression
Anhedonia, the inability to seek-out and experience pleasure, is a common symptom in depression that predicts treatment-resistance and is sometimes exacerbated by first-line antidepressants.
- Trial name
- DBA (NCT06132581)
- Testing
- Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Florida State University
HIV, HIV - Human Immunodeficiency Virus
Intervention to Reduce HIV Related Stigma Among Pregnant and Postpartum Women
Purpose of this Study: The main purpose of this study is to adapt an existing evidence-based intervention, Project Accept Post-Test Support Services (PTSS) Module 3, specifically for pregnant and postpartum women living with HIV…
- Conditions
- HIV, HIV - Human Immunodeficiency Virus, Postpartum, Pregnancy
- Trial name
- WAT (NCT07064928)
- Testing
- Adapted Project Accept's Post-Test Support Services (PTSS) Module 3
- Where
- Ghana
- Volunteers
- 163 people
- Sponsor
- University of California, San Francisco
Depressive Symptoms, Multiple Chronic Conditions
Resourcefulness Intervention With Parents of Technology-Dependent Children
Technology-dependent children, those who live at home but rely on medical equipment such as mechanical ventilation or feeding tubes, require complex care for their chronic condition.
- Conditions
- Depressive Symptoms, Multiple Chronic Conditions, Family Caregivers
- Trial name
- NCT03301831
- Testing
- Resourcefulness Training
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Treatment Resistant Depression, Elderly Depression (≥65y.o.)
Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-burst, Functional Imaging Guided, in the Treatment of Depression in Elderly Subjects With Cognitive Impairment
This trial aims at testing a new intensive, personalized functional targeting, transcranial magnetic stimulation technique for elderly patients (aged ≥ 65 years) suffering from a current treatment resistant depressive episode to…
- Trial name
- OLDEP-TBS (NCT07188753)
- Testing
- transcranial magnetic stimulation by accelerated & high-dose theta-burst, functional imaging guided, i
- Volunteers
- 186 people
- Sponsor
- Rennes University Hospital
Stroke, Quality of Life
Problem-Solving Therapy for Depressive Symptoms and Quality of Life in Stroke Survivor-Caregiver Dyads
The purpose of this feasibility study is to determine whether it is practical and helpful to provide problem-solving therapy to stroke survivors and their spouses/partners (caregivers) together.
- Conditions
- Stroke, Quality of Life, Depression
- Trial name
- NCT04035681
- Testing
- Problem-Solving Therapy, Stroke-Related Health Education
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Allina Health System
Major Depression
Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression.
- Trial name
- NCT00285766
- Testing
- Selegiline Transdermal System
- Where
- 15 sites in United States
- Volunteers
- 300 people
- Sponsor
- Somerset Pharmaceuticals
Major Depressive Disorder
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.
- Trial name
- NCT05593029
- Testing
- SEP-363856
- Where
- 77 sites in United States, Bulgaria and 5 more
- Volunteers
- 929 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
- Trial name
- NCT00358631
- Testing
- SSR149415
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Sanofi
Treatment Resistant Depression (TRD)
Neuronavigated aiTBS for TRD
The purpose of this study is to confirm the efficacy of two recently introduced repetitive transcranial magnetic stimulation (rTMS) interventions - accelerated intermittent theta-burst stimulation (aiTBS) and individualized…
- Trial name
- NCT07329153
- Testing
- aiTBS
- Where
- 3 sites in United States
- Volunteers
- 247 people
- Sponsor
- University of Texas Southwestern Medical Center
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder…
- Trial name
- AVENUE (NCT07227454)
- Testing
- Esketamine, Midazolam
- Where
- 49 sites in United States, Brazil and 5 more
- Volunteers
- 258 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorders, Anxiety Disorders
Stress, Anxiety, and Mood Group Therapy
The purpose of this study is to identify cognitive mechanisms that might facilitate treatment response for individuals experiencing depression and/or anxiety.
- Trial name
- NCT03855683
- Testing
- Unified Protocol for The Treatment of Emotional Disorders
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Palo Alto University
Major Depressive Disorder, Depression
TC-5214 as add-on the Treatment of Major Depressive Disorder
This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India.
- Trial name
- NCT00692445
- Testing
- TC-5214 + citalopram
- Where
- 27 sites in United States, India
- Volunteers
- 574 people
- Sponsor
- Targacept Inc.
Bipolar Disorder, Depression
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I…
- Trial name
- NCT02670538
- Testing
- Cariprazine
- Where
- 89 sites in United States, Bulgaria and 6 more
- Volunteers
- 493 people
- Sponsor
- Forest Laboratories
Depression, Major Depressive Disorder
Study of Naltrexone-Induced Blockade of Antidepressant Effects
The goal of this study is to determine whether antidepressant placebo effects and contextual cues broadly, can be blocked by one single dose of the µ-opioid antagonist naltrexone.
- Trial name
- SONRISA2 (NCT04322526)
- Testing
- Naltrexone 50 Mg Oral Tablet
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Marta Peciña, MD PhD
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without…
- Trial name
- NCT07065240
- Testing
- SPT-300
- Where
- 61 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Obesity, Major Depressive Disorder
Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)
To determine whether individuals who suffer from depression and obesity are able to lose weight and show improvements in mood and cardiovascular disease risk factors following 20 weeks of a combined treatment of…
- Conditions
- Obesity, Major Depressive Disorder, Dysthymic Disorder, Cardiovascular Disease
- Trial name
- TODI (NCT01692574)
- Testing
- Behavior Modification for Weight Loss, Alternative Approach to Weight Loss, Cognitive-Behavior Therapy for Depression
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of Pennsylvania
Autism, Autism Spectrum Disorder
The Supplementation Therapy in Autism and Response to Treatment Study
In addition to the "core" symptoms of ASD (i.e., impaired communication, impaired reciprocal social interaction and restricted, repetitive and stereotyped patterns of behaviors or interests), it is estimated that up to 70% of…
- Conditions
- Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Asperger Syndrome
- Trial name
- START (NCT06187090)
- Testing
- Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Udine
Depression, Depressive Symptom
Auricular Concha Electro-acupuncture for the Treatment of Depression
The objective of this study was to compare the therapeutic effects of Auricular Concha Electro-acupuncture and Citalopram on patients with major depressive disorder (MDD).
- Conditions
- Depression, Depressive Symptom, Depressive Disorder
- Trial name
- NCT03607331
- Testing
- Auricular vagus nerve stimulation, Citalopram
- Where
- China
- Volunteers
- 106 people
- Sponsor
- China Academy of Chinese Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.